Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F. Ambinder

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
JCO Global Oncology|April 28, 2021
Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated LymphomaSamantha L Vogt, Moosa Patel, Atul Lakha, et al.
Blood Advances|December 16, 2017
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamideYvette L Kasamon, Richard F Ambinder, Ephraim J Fuchs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 20, 2012
Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma riskShehnaz K Hussain, Weiming Zhu, Shen-Chih Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2018
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M Haverkos, Lynda Villagomez, et al.
Infectious Agents and Cancer|September 28, 2024
Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational studySamantha L Vogt, Garrick Laudin, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2017
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple MyelomaNilanjan Ghosh, Xiaobu Ye, Hua-Ling Tsai, et al.
British Journal of Haematology|June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experienceB Douglas Smith, Richard J Jones, Shing M Lee, et al.
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
Blood|April 21, 2023
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemiaAmy E DeZern, Marianna Zahurak, Heather J Symons, et al.
Science Translational Medicine|May 22, 2015
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myelomaKimberly A Noonan, Carol A Huff, Janice Davis, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
JCO Global Oncology|April 28, 2021
Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated LymphomaSamantha L Vogt, Moosa Patel, Atul Lakha, et al.
Blood Advances|December 16, 2017
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamideYvette L Kasamon, Richard F Ambinder, Ephraim J Fuchs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 20, 2012
Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma riskShehnaz K Hussain, Weiming Zhu, Shen-Chih Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2018
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M Haverkos, Lynda Villagomez, et al.
Infectious Agents and Cancer|September 28, 2024
Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational studySamantha L Vogt, Garrick Laudin, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2017
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple MyelomaNilanjan Ghosh, Xiaobu Ye, Hua-Ling Tsai, et al.
British Journal of Haematology|June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experienceB Douglas Smith, Richard J Jones, Shing M Lee, et al.
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
Blood|April 21, 2023
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemiaAmy E DeZern, Marianna Zahurak, Heather J Symons, et al.
Science Translational Medicine|May 22, 2015
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myelomaKimberly A Noonan, Carol A Huff, Janice Davis, et al.
Pageof 22